Question · asked by 1 review

Erythropoietin (subcutaneous or intravenous at varying dosages) vs placebo: Health‐related quality of life

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Erythropoietin (subcutaneous or intravenous at varying dosages) vs placebo
Health‐related quality of life · anemia in patients with rheumatoid arthritis
Erythropoiesis‐stimulating agents for anemia in rheumatoid arthritis (2013) · Cochrane Headline outcomes only
no estimate extracted3 studies · 136 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Erythropoiesis‐stimulating agents for anemia in rheumatoid arthritis
2013 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.